231 related articles for article (PubMed ID: 19738426)
1. Anti-angiogenic properties of metronomic topotecan in ovarian carcinoma.
Merritt WM; Danes CG; Shahzad MM; Lin YG; Kamat AA; Han LY; Spannuth WA; Nick AM; Mangala LS; Stone RL; Kim HS; Gershenson DM; Jaffe RB; Coleman RL; Chandra J; Sood AK
Cancer Biol Ther; 2009 Aug; 8(16):1596-603. PubMed ID: 19738426
[TBL] [Abstract][Full Text] [Related]
2. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
3. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
[TBL] [Abstract][Full Text] [Related]
4. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
Kamat AA; Kim TJ; Landen CN; Lu C; Han LY; Lin YG; Merritt WM; Thaker PH; Gershenson DM; Bischoff FZ; Heymach JV; Jaffe RB; Coleman RL; Sood AK
Cancer Res; 2007 Jan; 67(1):281-8. PubMed ID: 17210709
[TBL] [Abstract][Full Text] [Related]
5. Metronomic activity of CD44-targeted hyaluronic acid-paclitaxel in ovarian carcinoma.
Lee SJ; Ghosh SC; Han HD; Stone RL; Bottsford-Miller J; Shen DY; Auzenne EJ; Lopez-Araujo A; Lu C; Nishimura M; Pecot CV; Zand B; Thanapprapasr D; Jennings NB; Kang Y; Huang J; Hu W; Klostergaard J; Sood AK
Clin Cancer Res; 2012 Aug; 18(15):4114-21. PubMed ID: 22693353
[TBL] [Abstract][Full Text] [Related]
6. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
[TBL] [Abstract][Full Text] [Related]
7. Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer.
Di Desidero T; Xu P; Man S; Bocci G; Kerbel RS
Oncotarget; 2015 Dec; 6(40):42396-410. PubMed ID: 26623560
[TBL] [Abstract][Full Text] [Related]
8. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor.
Kumar S; Mokhtari RB; Sheikh R; Wu B; Zhang L; Xu P; Man S; Oliveira ID; Yeger H; Kerbel RS; Baruchel S
Clin Cancer Res; 2011 Sep; 17(17):5656-67. PubMed ID: 21788355
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer.
Landen CN; Lu C; Han LY; Coffman KT; Bruckheimer E; Halder J; Mangala LS; Merritt WM; Lin YG; Gao C; Schmandt R; Kamat AA; Li Y; Thaker P; Gershenson DM; Parikh NU; Gallick GE; Kinch MS; Sood AK
J Natl Cancer Inst; 2006 Nov; 98(21):1558-70. PubMed ID: 17077358
[TBL] [Abstract][Full Text] [Related]
10. Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer.
Cruz-Muñoz W; Di Desidero T; Man S; Xu P; Jaramillo ML; Hashimoto K; Collins C; Banville M; O'Connor-McCourt MD; Kerbel RS
Angiogenesis; 2014 Jul; 17(3):661-73. PubMed ID: 24569856
[TBL] [Abstract][Full Text] [Related]
11. Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models.
Lu C; Shahzad MM; Moreno-Smith M; Lin YG; Jennings NB; Allen JK; Landen CN; Mangala LS; Armaiz-Pena GN; Schmandt R; Nick AM; Stone RL; Jaffe RB; Coleman RL; Sood AK
Cancer Biol Ther; 2010 Feb; 9(3):176-82. PubMed ID: 20009575
[TBL] [Abstract][Full Text] [Related]
12. VEGFR2 heterogeneity and response to anti-angiogenic low dose metronomic cyclophosphamide treatment.
Patten SG; Adamcic U; Lacombe K; Minhas K; Skowronski K; Coomber BL
BMC Cancer; 2010 Dec; 10():683. PubMed ID: 21159176
[TBL] [Abstract][Full Text] [Related]
13. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway.
Lin YG; Kunnumakkara AB; Nair A; Merritt WM; Han LY; Armaiz-Pena GN; Kamat AA; Spannuth WA; Gershenson DM; Lutgendorf SK; Aggarwal BB; Sood AK
Clin Cancer Res; 2007 Jun; 13(11):3423-30. PubMed ID: 17545551
[TBL] [Abstract][Full Text] [Related]
14. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers.
Tsunetoh S; Terai Y; Sasaki H; Tanabe A; Tanaka Y; Sekijima T; Fujioka S; Kawaguchi H; Kanemura M; Yamashita Y; Ohmichi M
Cancer Biol Ther; 2010 Dec; 10(11):1137-46. PubMed ID: 20935474
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia-inducible factor 1alpha (HIF-1alpha) correlated with tumor growth and apoptosis in ovarian cancer.
Jiang H; Feng Y
Int J Gynecol Cancer; 2006; 16 Suppl 1():405-12. PubMed ID: 16515634
[TBL] [Abstract][Full Text] [Related]
16. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
17. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
[TBL] [Abstract][Full Text] [Related]
18. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Puppo M; Battaglia F; Ottaviano C; Delfino S; Ribatti D; Varesio L; Bosco MC
Mol Cancer Ther; 2008 Jul; 7(7):1974-84. PubMed ID: 18645007
[TBL] [Abstract][Full Text] [Related]
19. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Soffer SZ; Moore JT; Kim E; Huang J; Yokoi A; Manley C; O'Toole K; Stolar C; Middlesworth W; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
[TBL] [Abstract][Full Text] [Related]
20. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
Shen FZ; Wang J; Liang J; Mu K; Hou JY; Wang YT
Int J Exp Pathol; 2010 Feb; 91(1):10-6. PubMed ID: 20096070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
